IVIG plus Glucocorticoids versus IVIG Alone in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19: A Systematic Review and Meta-Analysis

Внутривенный иммуноглобулин в сочетании с глюкокортикостероидами по сравнению с монотерапией внутривенным иммуноглобулином при мультисистемном воспалительном синдроме у детей (MIS-C), ассоциированном с COVID-19: систематический обзор и метаанализ
Shikha Yadav, Robin Rauniyar, Aman Mishra, Sanjeev Kharel, Subarna Giri, Rohit Rauniyar, Gajendra Chaudhary
2022-03-29

Adjunctive immunomodulatory therapyIVIG plus glucocorticoidsMultisystem inflammatory syndrome in childrenSystematic review and meta-analysisTreatment failure
Background. There is limited information available regarding the management of multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2. We performed a systematic review and meta-analysis to evaluate the optimal treatment using IVIG alone versus IVIG plus glucocorticoids. Methods. PubMed, Google Scholar, EMBASE, and Cochrane databases were searched along with other secondary searches. Studies published within the time frame of January 2020 to August 2021 were included. We screened records, extracted data, and assessed the quality of the studies using NOS. Studies that directly compare the two treatment groups were included. Analyses were conducted using the random-effects model (DerSimonian-Laird analysis) if I2 > 50% and fixed-effects model was used if I2 < 50%. Results. We included three studies in the final quantitative analysis. The initial therapy with the IVIG plus glucocorticoids group significantly lowered the risk of treatment failure (OR 0.57, 95% CI (0.42, 0.79), I2 45.36%) and the need for adjunctive immunomodulatory therapy (OR 0.27, 95% CI (0.20, 0.37), I2 0.0%). The combination therapy showed no significant reduction in occurrence of left ventricular dysfunction (OR 0.79, 95% CI (0.34, 1.87), I2 58.44%) and the need for inotropic support (OR 0.83, 95% CI (0.35, 1.99), I2 75.40%). Conclusion. This study supports the use of IVIG with glucocorticoids compared to IVIG alone, as the combination therapy significantly lowered the risk of treatment failure and the need for adjunctive immunomodulatory therapy.
1
A systematic review and meta-analysis of three comparative studies evaluated IVIG plus glucocorticoids versus IVIG alone for MIS-C associated with COVID-19.
2
Combination therapy did not significantly reduce left ventricular dysfunction (OR 0.79, 95% CI 0.34–1.87) or the need for inotropic support (OR 0.83, 95% CI 0.35–1.99).
3
IVIG plus glucocorticoids significantly reduced the need for adjunctive immunomodulatory therapy (OR 0.27, 95% CI 0.20–0.37; I2 0.0%).
4
Initial combination therapy significantly reduced treatment failure compared with IVIG alone (OR 0.57, 95% CI 0.42–0.79; I2 45.36%).
5
The findings support using IVIG with glucocorticoids rather than IVIG alone as initial treatment for MIS-C, particularly to reduce treatment failure and escalation of immunomodulatory therapy.

Multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2

Comparative treatment outcomes of IVIG plus glucocorticoids versus IVIG alone, including treatment failure, need for adjunctive immunomodulatory therapy, left ventricular dysfunction, and inotropic support

Publication Details
Publication Date
2022-03-29
Journal
Publisher
ISSN
Cited by
14
Access Type
Author Information
Authors
Shikha Yadav
Robin Rauniyar
Aman Mishra
Sanjeev Kharel
Subarna Giri
Rohit Rauniyar
Gajendra Chaudhary
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%